Acquisition of product portfolio from Roche completed

Acquisition of product portfolio from Roche completed

 •  Competition authorities have approved the acquisition 

 •  Meda's position in key therapy areas strengthened

 •  Sales level of about 500 MSEK

 •  Purchase price 120 MEUR, equivalent to about 2,3 times sales


On 15 August 2008, Meda announced that it reached agreement regarding
acquisition of four well established pharmaceuticals from the Swiss pharma
company Roche - pending approval from competition authorities. The authorities
have now approved the purchase, and Meda is taking over the products.

The acquired products have strong brand names and the total sales level is 500
MSEK. No employees will transfer from Roche to Meda in conjunction with the
acquisition. Meda acquires world-wide rights to the products and the most
important markets are Germany, Spain, Switzerland, USA and France. Meda
strengthens its position in key therapy areas; Cardiology, CNS and Pain /
Inflammation. 

The purchase price is 120 MEUR, corresponding to approximately 1 160 MSEK and
equivalent to about 2,3 times sales. An up-front of 110 MEUR has been paid at
closing of the transaction and the remaining 10 MEUR will be paid upon
completion and assignment of certain agreements.
The four acquired Roche products are:

Marcoumar (phenprocoumon) is a well-established anticoagulant. This product fits
perfectly into Meda's cardiovascular product portfolio. The largest market is
Germany and the total sales level is about 200 MSEK.

Torem (torasemide) is a loop diuretic. It is also marketed using trademarks such
as Demadex, Dilutol and Toradiur in more than 30 countries - also in the USA and
in Japan. The product fits well in Meda's antihypertensive product range. The
sales level is about 180 MSEK.

Tilcotil	(tenoxicam) is a NSAID drug for the treatment of painful inflammatory
and degenerative disorders of the musculoskeletal system such as rheumatoid and
osteoarthritis, and arthrosis. The product is also marketed using the trademarks
Mobiflex, Tilatil, Tilcitin and Alganex. Tilcotil fits perfectly into Meda's
therapy area Pain / Inflammation. The sales level is approximately 70 MSEK.

Aurorix (moclobemide) is a MAO-A inhibitor and a well-known antidepressant for
specialists to prescribe. The sales level is approximately 50 MSEK.



For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878


MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships are fundamental factors that drive the
company's strategy. Meda is represented by its own organisations in about 40
countries. Meda's products are sold in 120 countries worldwide. The Meda share
is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit
www.meda.se.